Cost-effectiveness analysis of a large jail-based methadone maintenance treatment continuation program in New Mexico

被引:7
|
作者
Horn, Brady P. [1 ,2 ]
Li, Xiaoxue [1 ]
McCrady, Barbara [2 ,3 ]
Guerin, Paul [4 ]
French, Michael T. [5 ]
机构
[1] Univ New Mexico, Dept Econ, MSC 05 3060,1 Univ New Mexico, Albuquerque, NM 87131 USA
[2] Univ New Mexico, Ctr Alcoholism Subst Abuse & Addict CASAA, 2650 Yale SE MSC11-6280, Albuquerque, NM 87106 USA
[3] Univ New Mexico, Dept Psychol, MSC 05 3060,1 Univ New Mexico, Albuquerque, NM 87131 USA
[4] Univ New Mexico, Inst Social Res, 1915 Las Lomas, Albuquerque, NM 87131 USA
[5] Univ Miami, Miami Herbert Business Sch, Dept Hlth Management & Policy, Coral Gables, FL 33124 USA
关键词
Opioid use disorder; Methadone maintenance; Cost-effectiveness analysis; Jail; Recidivism; SUBSTANCE-ABUSE TREATMENT; ECONOMIC-EVALUATION; DRUG-ABUSE; PRISON; ADDICTION; COMMUNITY; COURT;
D O I
10.1016/j.jsat.2020.108042
中图分类号
B849 [应用心理学];
学科分类号
040203 ;
摘要
The U.S. has the second-highest incarceration rate in the world and spends more than $80 billion annually to house inmates. The clinical research literature suggests that methadone maintenance treatment (MMT) is an effective method to treat opioid use disorders (OUD) and that jails are a potentially valuable environment to implement MMT. Currently, jail-based MMT is rarely implemented in practice, due in part to resource limitations and other economic considerations. The primary goal of this study was to perform a cost-effectiveness analysis (CEA) of jail-based MMT using data from a unique MMT continuation program located in a large urban jail in New Mexico. Recidivism data were collected for a three-year period both before and after incarceration, and quasi-control groups were constructed from both substance-using and general populations within the jail. Base models show that inmates enrolled in jail-based MMT exhibited significantly fewer days of incarceration due to recidivism (29.33) than a group of inmates with OUDs who did not receive MMT. Economic estimates indicate that it cost significantly less ($23.49) to reduce an incarcerated day using jail-based MMT than incarceration per se ($116.49). To mitigate potential sample selection bias, we used both propensity-score-matching and difference-in-differences estimators, which provided comparable estimates when using the OUD non-MMT comparison group. Difference-in-differences models find that, on average, MMT reduced recidivism by 24.80 days and it cost $27.78 to reduce an incarcerated day using jail-based MMT. Assuming a willingness to pay threshold of the break-even cost of reducing one incarcerated day, we estimate a 93.3% probability that this MMT program is cost-effective. Results were not as strong or consistent when using other comparison groups (e.g., alcohol-detoxified and general-population inmates). Overall, results suggest that it costs substantially less to provide jail-based MMT than incarceration alone. Jail administrators and policymakers should consider incorporating MMT in other jail systems and settings.
引用
收藏
页数:8
相关论文
共 50 条
  • [31] Cost-Effectiveness Analysis of Tisagenlecleucel for the Treatment of Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma in the United States
    Qi, Cynthia Z.
    Bollu, Vamsi
    Yang, Hongbo
    Dalal, Anand
    Zhang, Su
    Zhang, Jie
    CLINICAL THERAPEUTICS, 2021, 43 (08) : 1300 - +
  • [32] A Cost-Effectiveness Analysis of Axicabtagene Ciloleucel versus Tisagenlecleucel in the Treatment of Diffuse Large B-cell Lymphoma Based on a Real-World French Registry
    Ray, Markqayne
    Castaigne, Jean-Gabriel
    Zang, Alexandra
    Patel, Anik
    Hancock, Elizabeth
    Brighton, Nicholas
    Bachy, Emmanuel
    ADVANCES IN THERAPY, 2024, 41 (11) : 4282 - 4298
  • [33] Exploring the cost-effectiveness of a Dutch collaborative stepped care intervention for the treatment of depression and/or anxiety when adapted to the Australian context: a model-based cost-utility analysis
    Lee, Y. Y.
    Harris, M. G.
    Whiteford, H. A.
    Davidson, S. K.
    Chatterton, M. L.
    Stockings, E. A.
    Mihalopoulos, C.
    EPIDEMIOLOGY AND PSYCHIATRIC SCIENCES, 2021, 30
  • [34] Olaparib plus bevacizumab as a first-line maintenance treatment for patients with advanced ovarian cancer by molecular status: an updated PAOLA-1 based cost-effectiveness analysis
    Zhu, Youwen
    Yang, Qiuping
    Liu, Kun
    Cao, Hui
    Zhu, Hong
    JOURNAL OF GYNECOLOGIC ONCOLOGY, 2024, 35 (01)
  • [35] The cost-effectiveness of stepped care for the treatment of anxiety disorders in adults: A model-based economic analysis for the Australian setting
    Stiles, Jay A.
    Chatterton, Mary Lou
    Le, Long Khanh-Dao
    Lee, Yong Yi
    Whiteford, Harvey
    Mihalopoulos, Cathrine
    JOURNAL OF PSYCHOSOMATIC RESEARCH, 2019, 125
  • [36] Cost-Effectiveness Analysis of Etanercept 25 mg Maintenance Therapy After Treatment With Etanercept 50 mg for Moderate Rheumatoid Arthritis in the PRESERVE Trial in Japan
    Hirose, Tomohiro
    Kawaguchi, Isao
    Murata, Tatsunori
    Atsumi, Tatsuya
    VALUE IN HEALTH REGIONAL ISSUES, 2022, 28 : 105 - 111
  • [37] Model-based cost-effectiveness analysis of external beam radiation therapy for the treatment of localized prostate cancer: a systematic review
    Abreha, Solomon Kibret
    COST EFFECTIVENESS AND RESOURCE ALLOCATION, 2019, 17 (1)
  • [38] Model-based cost-effectiveness analysis of external beam radiation therapy for the treatment of localized prostate cancer: a systematic review
    Solomon Kibret Abreha
    Cost Effectiveness and Resource Allocation, 17
  • [39] Autologous stem-cell transplantation and maintenance therapy for transplant-eligible multiple myeloma patients: cost-effectiveness analysis based on a network meta-analysis
    Wu, Weijia
    Wang, Yannan
    Lou, Yingting
    Fan, Xiaoyuan
    Yang, Wenqianzi
    Tang, Fengyuan
    Zhao, Zixuan
    Dong, Hengjin
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2025,
  • [40] The cost-effectiveness of pegaspargase versus native asparaginase for first-line treatment of acute lymphoblastic leukaemia: a UK-based cost-utility analysis
    Hu, Xingdi
    Wildman, Kingsley P.
    Basu, Subham
    Lin, Peggy L.
    Rowntree, Clare
    Saha, Vaskar
    HEALTH ECONOMICS REVIEW, 2019, 9 (01)